specific quality criteria developed by the authors. RESULTS: We found 45 comparative studies in 43 publications. Asthma (14 studies) and psychiatric illness (12 studies) were most commonly investigated. In 33 studies, interventions were educational, 20 had multiple components and 23 did not appear to be linked to proven reasons for non-adherence. No studies assessed management of unintentional non-adherence. No study met all quality criteria. Study quality has not improved with time, as some better studies are over ten years old. Many studies used inadequate or unidentifiable adherence measures. Critically, many were too small or not randomised. All studies assumed that patients were prescribed appropriate therapy for their condition, and no assessment of treatment quality was made by any study. Reporting of adherence and outcome results was often unclear. Cost data were poorer quality than outcome data, using average or estimated costs and omitting some cost elements. Nine studies carried out incremental economic analysis. CONCLUSIONS: We were not able to make definitive conclusions about the cost-effectiveness of medication adherence enhancing interventions due to the heterogeneity of the studies found and incomplete reporting of results. Important policy decisions need to be made about non-adherence, however, they are currently being made in a vacuum of adequate information. Medication adherence-enhancing interventions must be based on reasons for non-adherence and be evaluated using accepted clinical and economic quality criteria.

**PHP2**

**THE MEDINET-PROJECT—A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS**

Sterz R1, Lebmeier M2, Simon U3

1Abbott GmbH & Co. KG, Ludwigshafen, Rhineland-Palatinate, Germany; 2Sheffield University, Sheffield, UK; 3ES-Q-Lab, Lauf, Bavaria, Germany

OBJECTIVES: To study medication compliance patterns regarding dosing, timing and adherence under real life conditions. Using a new electronic blister pack system. METHODS: A total of 37 volunteers from three study centers were each furnished with an electronic blister holder ("monitor") and three blister packs containing 14 placebo capsules each (trial duration: six-weeks). The monitor measured the disruption of conductive lines printed on aluminum carrier foil under each capsule and stored this information (date and time) for evaluation at the end of the study. Patients had to take out one capsule daily in the morning over the entire study period. Also patients received a CRF and a radio-controlled clock such that date and time of the event could be manually recorded by the patient as well. Data were considered accurate if the information stored in the monitor and the corresponding CRF entries were within a time window of ±15 min. RESULTS: All recordings of the electronically stored information matched the data documented on the CRFs. This indicates the accurate documentation of the volunteers, as well as the correct functioning of the monitors. Evaluation of the data, however, showed a wide inra—as well as interindividual variation in the time patterns of the volunteers. Three clusters of time preference were detected—mornings, noon and late night. Further, periods of non-compliance ("drug holidays") as well as lack of adherence (discontinuation of medication before the end of the study period of six-weeks) could be documented. CONCLUSIONS: The use of the new electronic blister system improves compliance measurement under real life conditions. Combining compliance information with other outcome parameters will help in better quantifying and optimizing the impact of patient compliance on clinical and economic outcomes under real life conditions.